Syros Pharmaceuticals Stock Forecast, Price & News

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Syros Pharmaceuticals stock.
View analyst ratings for Syros Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Syros Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Syros Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Syros Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Syros Pharmaceuticals.

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) issued its earnings results on Thursday, March, 4th. The company reported ($0.62) EPS for the quarter, missing analysts' consensus estimates of ($0.54) by $0.08. Syros Pharmaceuticals had a negative net margin of 743.58% and a negative trailing twelve-month return on equity of 111.54%.
View Syros Pharmaceuticals' earnings history.

Syros Pharmaceuticals' stock was trading at $5.15 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SYRS shares have increased by 45.8% and is now trading at $7.51.
View which stocks have been most impacted by COVID-19.

8 brokerages have issued 12 month target prices for Syros Pharmaceuticals' stock. Their forecasts range from $13.00 to $20.00. On average, they anticipate Syros Pharmaceuticals' stock price to reach $17.57 in the next year. This suggests a possible upside of 134.0% from the stock's current price.
View analysts' price targets for Syros Pharmaceuticals or view top-rated stocks among Wall Street analysts.

3 employees have rated Syros Pharmaceuticals CEO Nancy Simonian on Glassdoor.com. Nancy Simonian has an approval rating of 100% among Syros Pharmaceuticals' employees. This puts Nancy Simonian in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Syros Pharmaceuticals include Zentalis Pharmaceuticals (ZNTL), Aurinia Pharmaceuticals (AUPH), Shattuck Labs (STTK), ImmunoGen (IMGN), Seres Therapeutics (MCRB), Kronos Bio (KRON), ADC Therapeutics (ADCT), Ironwood Pharmaceuticals (IRWD), Endo International (ENDP), PMV Pharmaceuticals (PMVP), Organogenesis (ORGO), Heron Therapeutics (HRTX), Arcutis Biotherapeutics (ARQT), Kiniksa Pharmaceuticals (KNSA) and Zymeworks (ZYME).
View all of SYRS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), ImmunoGen (IMGN), VBI Vaccines (VBIV), Amarin (AMRN), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR) and Pfizer (PFE).

(SYRS) raised $60 million in an IPO on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."

Syros Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (7.80%), Nikko Asset Management Americas Inc. (7.80%), BlackRock Inc. (5.92%), Samsara BioCapital LLC (3.90%), Orbimed Advisors LLC (2.78%) and Artal Group S.A. (1.33%). Company insiders that own Syros Pharmaceuticals stock include Eric R Olson, Jeremy P Springhorn, Mark J Alles, Richard A Young, Srinivas Akkaraju and Venture Fund Vii LP Arch.
View institutional ownership trends for Syros Pharmaceuticals.

SYRS stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Nuveen Asset Management LLC, Credit Suisse AG, New York State Common Retirement Fund, Northern Trust Corp, Virtus ETF Advisers LLC, ETF Managers Group LLC, and State of Wisconsin Investment Board. Company insiders that have sold Syros Pharmaceuticals company stock in the last year include Eric R Olson, Richard A Young, and Srinivas Akkaraju.
View insider buying and selling activity for Syros Pharmaceuticals or view top insider-selling stocks.

SYRS stock was acquired by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Samsara BioCapital LLC, Artal Group S.A., Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Citigroup Inc., Ikarian Capital LLC, and Renaissance Technologies LLC. Company insiders that have bought Syros Pharmaceuticals stock in the last two years include Jeremy P Springhorn, Mark J Alles, and Srinivas Akkaraju.
View insider buying and selling activity for Syros Pharmaceuticals or or view top insider-buying stocks.

Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SYRS stock can currently be purchased for approximately $7.51.

Syros Pharmaceuticals has a market capitalization of $422.04 million and generates $1.98 million in revenue each year. The company earns $-75,440,000.00 in net income (profit) each year or ($1.88) on an earnings per share basis.

Syros Pharmaceuticals employs 83 workers across the globe.

The official website for Syros Pharmaceuticals is www.syros.com.

Syros Pharmaceuticals is headquartered at 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139.

Syros Pharmaceuticals' mailing address is 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-744-1340 or via email at [email protected]